Pancreatic cancer precision medicine trial aims to be accessible to more patients
A clinical trial at Addenbrooke's Hospital, Cambridge is the first to explore using precision immunotherapies to treat pancreatic cancer, one of the hardest to treat forms of cancer. The trial will pilot a new system for running clinical trials in the UK intended to make them faster and more accessible for patients.
Precision medicine has transformed the treatment of many cancer's yet little has changed for people with pancreatic cancer. A new trial led by Dr Pippa Corrie, consultant medical oncologist at Addenbrooke's Hospital, aims to change this by being the first to trial a precision medicine immunotherapy approach in this challenging cancer.
Dr Pippa Corrie, consultant medical oncologist, PemOla Trial Lead
The trial is the first to pilot a new "Just in time" scheme run by the National Institute for Health and Care Research (NIHR), which could reduce the time needed for hospitals to join a clinical trial from months to only days. If successful, the scheme could allow more patients to benefit from clinical trials without the need to travel to specialist hospitals. The PemOla trial is funded by the Efficacy and Mechanism Evaluation (EME) Programme, a partnership between the NIHR and the Medical Research Council (MRC), and supported by MSD who are providing the study drug. The trial is being run from the Cambridge Clinical Trials Unit and sponsored by Cambridge University Hospitals NHS Foundation Trust.
For full article visit: CUH news
Latest from CCTU
National Patient Led Research Hub celebrates tenth anniversary
A national team based in Cambridge are celebrating ten years of helping people living with rare diseases to develop their own research ideas. The hub has…
Hope for MS patients as Cambridge trial suggests drug combination may repair nerve damage
Early findings from a clinical trial in Cambridge suggest a combination of metformin, a diabetes drug, and clemastine, an antihistamine, can help repair…
Prospective study into controversial brain cyst syndrome is world first
The world’s first study of its kind highlights the potential value of surgery to treat a specific kind of brain cyst that blights the lives of patients.
